| 2026-08-27 16:15 |
8-K |
["2.01"] |
tender offer |
1.00
|
Merger completed: argenx acquired Forte Biosciences at $77/share via tender offer and Section 251(h) merger. |
SEC · detail |
| 2026-08-27 09:27 |
SC TO-T |
|
tender offer |
1.00
|
Completed tender offer: ARGENX acquired Forte Biosciences for $77/share; merger consummated on August 27, 2026. |
SEC · detail |
| 2026-08-27 09:25 |
SC 14D9 |
|
tender offer |
1.00
|
Merger completed: argenx acquired Forte Biosciences at $77/share via tender offer; delisting effective. |
SEC · detail |
| 2026-08-21 16:01 |
SC 14D9 |
|
tender offer |
0.98
|
SC 14D9/A amendment to tender offer by argenx BV subsidiary at $77/share for Forte Biosciences common stock. |
SEC · detail |
| 2026-08-19 07:48 |
SC TO-T |
|
tender offer |
0.98
|
Argenx SE acquiring Forte Biosciences for $77/share via tender offer; HSR clearance obtained. |
SEC · detail |
| 2026-08-19 06:00 |
SC 14D9 |
|
tender offer |
0.98
|
SC 14D-9/A amendment confirms tender offer by argenx BV subsidiary at $77/share with HSR approval satisfied. |
SEC · detail |
| 2026-08-06 07:36 |
SC 14D9 |
|
tender offer |
0.98
|
SC 14D-9 filed by Forte Biosciences responding to argenx's $77/share tender offer and merger agreement dated July 26, 2026. |
SEC · detail |
| 2026-07-27 06:06 |
8-K |
["1.01"] |
merger agreement |
0.99
|
Forte Biosciences entered definitive merger agreement with argenx BV for $77/share cash acquisition via tender offer. |
SEC · detail |
| 2026-07-09 08:05 |
8-K |
["7.01", "8.01", "9.01"] |
other |
0.05
|
8-K disclosure of Phase 1b clinical trial results and investor conference call; no M&A signals. |
SEC · detail |
| 2026-06-02 16:01 |
8-K |
["5.02", "5.07", "9.01"] |
other |
0.05
|
Routine 8-K reporting annual shareholder meeting results and equity plan approval; no M&A signals. |
SEC · detail |
| 2026-05-14 16:42 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine quarterly earnings release with no M&A-related content or strategic transaction indicators. |
SEC · detail |